Juniper Pharma Services has been selected by PharmAust Ltd. to reformulate monepantel (MPL) for its Phase II studies. PharmAust will also manufacture 20,000 capsules of the reformulated MPL solution for Juniper under GMP, ensuring that the Phase II data are admissible to regulators as part of any subsequent submissions.   MPL needs to be reformulated because of the unpleasant taste. While the Phase I study showed significant activity of MPL on tumor markers such as p70S6K and p-4E-BP1, complia...